Table 3: Demographics and baseline characteristics.


All ( n = 61) a TAC Only ( n = 41) CsA Only ( n = 20)

Age (yrs) 52 (35‒69) 51 (36‒69) 52 (35‒66)
Male 25 (41.0%) 10 (24.4%) 15 (75.0%)
Female 36 (59.0%) 31 (75.6%) 5 (25.0%)
African American 41 (67.2%) 30 (73.2%) 11 (55.0%)
Caucasian 18 (29.5%) 10 (24.4%) 8 (40.0%)
Other 2 (3.3%) 1 (2.4%) 1 (5.0%)
Causes of End-Stage Renal Failure
Diabetes Mellitus 29 (47.5%) 21 (51.2%) 8 (40.0%)
Hypertension 42 (68.9%) 25 (61.0%) 17 (85.0%)
Glomerular Disease 10 (16.4%) 9 (22.0%) 1 (5.0%)
Polycystic Disease 4 (6.6%) 4 (9.8%) 0 (0%)
Other/Unknown 6 (9.8%) 4 (9.8%) 2 (10.0%)
Average Time Post Transplant to Conversion to myfortic (months) 33 (1–97) 34 (1–97) 34 (1–94)
Time from Conversion to Enrollment in MPACT (months) 11 (4–19) 12 (6–19) 10 (4–17)
Daily myfortic dose at Conversion (mg) 1121 (360–2160) 992 (360–2160) 1385 (720–2160)

a Data are n(%) or mean(range).
*All patients regiments included daily prednisone use.